Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
|
|
- Brendan Terry
- 5 years ago
- Views:
Transcription
1 Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford
2 Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant depression Recent studies with ketamine
3 Clinical Approach to Diagnosis Baldwin et al, 2014
4 EU Community Studies of Anxiety Disorders Diagnosis 12 month Pharmacological prevalence (%) Treatment Specific phobia 6.4 N/A PTSD 2.9 SSRI Panic (± agoraphobia) 1.8 SSRI Agoraphobia (- panic) 2.0 SSRI Social Phobia 2.3 SSRI GAD 2.5 SSRI OCD 0.7 SSRI
5 SSRIs and SNRIs in Anxiety Disorders SSRI Paroxetine Fluoxetine Sertraline Citalopram Escitalopram Venlafaxine Duloxetine Licensed Indications (additional to major depression) GAD, Panic, SAD, OCD, PTSD OCD Panic, SAD, OCD, PTSD Panic GAD, Panic, SAD, OCD GAD, Panic, SAD GAD
6 Pregabalin in GAD Mode of action uncertain. Probably via blockade of a subunit of calcium channels Side effects profile different to SSRI. Somnolence dizziness, increased appetite. Loss of visual acuity reported rarely. Withdrawal symptoms can occur (insomnia, anxiety) Daily dose mg (2 or 3 x daily). No clear dose response Misuse potential Can be combined with antidepressants
7 NICE Guidelines for Anxiety Stepped Care Approach Psychological treatments preferred Generally recommend SSRIs if drug therapy needed. SNRI second line. Pregabalin third line (GAD). Benzodiazepines- maximum 2-4 weeks Continuation treatment generally indicated
8 Depression-threshold for prescribing (NICE) Antidepressants not recommended for mild depression (PHQ 9 < 15)- unless chronic symptoms or previous history of more severe depression PHQ Antidepressants or psychotherapy PHQ9 > 19 Antidepressants and psychotherapy Normally choose an SSRI in generic form (but not, if patient taking: triptans, NSAIDs, warfarin, heparin, aspirin)- Consider mirtazapine or use SSRI with gastroprotective medicine (except triptan).
9 Network Meta-Analysis of Antidepressant Efficacy in Major Depression Cipriani et al, 2018
10 Efficacy and Tolerability of Antidepressants in Major Depression Cipriani et al, 2018
11 Early Pharmacological Approaches to TRD (NICE) 1. Consider raising dose (allows time for natural recovery to start and to carry out further assessments) 2. Switch (initially another SSRI, or a better tolerated new generation antidepressant) 3. An antidepressant of a different pharmacological class that may be less well tolerated (eg a TCA (but not dosulepin),venlafaxine, or an MAOI)
12 Different Class vs SSRIs Switch in SSRI- Resistant patients Papakostos et al 2007
13 Further Management (NICE Guidelines) 1. Antidepressant combination (eg mirtazapine with SSRI or SNRI; in US bupropion plus SSRI popular) 2. Lithium augmentation 3. Atypical antipsychotic augmentation
14 Mirtazapine Addition to Ineffective SSRI/SNRI Treatment 480 depressed patients on SSRI/SNRI at least six weeks Randomised to mirtazapine addition (up to 30mg) or placebo. Primary outcome BDI at 12 weeks Adjusted difference in scores ( ; p= 0.087) Conclusion- No convincing evidence of clinical benefit
15 Meta-analysis of atypical antipsychotic augmentation of SSRI treatment Agent and study Olanzapine studies Shelton et al Shelton et al Corya et al Thase et al I Thase et al II Subtotal Risperidone studies Mahmoud et al Keitner et al Reeves et al Subtotal Quetiapine studies Khullar et al Mattingly et al McIntyre et al Earley et al El-Khalili et al Subtotal Aripiprazole studies Berman et al Berman et al Marcus et al Subtotal Treatment, n 6 / / / / / / / 62 4 / / 8 11 / 24 9 / / / / / / Control, n 2 / / / / / / / 33 2 / / 7 2 / 13 5 / / / / / / Odds ratio (fixed) (95% CI) Odds ratio (fixed) (95% CI) 6.00 (0.81, 44.35) 1.42 (0.74, 2.74) 1.97 (0.94, 4.13) 1.47 (0.74, 2.91) 2.37 (1.20, 4.70) 1.83 (1.30, 2.56) 2.32 (1.12, 4.83) 3.33 (1.30, 8.53) 2.25 (0.32, 15.76) 2.63 (1.51, 4.57) 9.55 (0.40, ) 4.65 (0.84, 25.66) 2.16 (0.62, 7.49) 1.63 (1.06, 2.50) 1.95 (1.25, 3.06) 1.89 (1.41, 2.54) 1.88 (1.11, 3.19) 2.49 (1.52, 4.08) 1.90 (1.13, 3.19) 2.09 (1.55, 2.81) Total (1.69, 2.37) Favours control Favours treatment SSRI, selective serotonin reuptake inhibitor; CI, confidence interval Nelson JC, Papakostas GI. Am J Psychiatry 2009;166:980-91
16 Meta-Analysis of Atypical Antipsychotic augmentation of SSRI Treatment (ii) Response rate 44.2% vs 29.9% Remission rate 30.7% vs 17.2% For Response NNT= 9 For Remission NNT= 9 Discontinuation (adverse effects) NNH= 17 (Papakostas and Nelson, 2009)
17 Network Meta-analysis of Augmentation Treatments for Resistant Depression (n= 6,700) * * * * Zhou et al, 2015
18 LQD Study Funded by NIHR Multi-centre-pragmatic study of lithium versus quetiapine as add-on therapy in patients with TRD (persisting depression despite having tried two or more antidepressants in current episode). 276 patients randomised openly to 12 months treatment Referral:
19
20 Ketamine as an Antidepressant Ketamine is an antagonist at glutamate NMDA receptors Used as general anaesthetic At sub-anaesthetic doses, intravenous ketamine can provide some temporary relief from depression in resistant depression (bipolar and unipolar)
21 Ketamine produces a rapid alleviation of depression in TRD Zarate et al 2006
22 Meta-analysis of Ketamine Remission in TRD McGirr et al, 2015
23 Subsequent Experience with Ketamine Transient antidepressant effect (1-7 days) confirmed in numerous controlled studies (NNT for response 3-5). Response not generally maintained with available glutamatergic agents (memantine, riluzole). Other NMDA and glutamate receptor antagonists developed by Industry not consistently effective in trials Intranasal s-ketamine may be effective and more useful for longer-term maintenance. Worries about longer-term adverse effects remain
24 Conclusions For anxiety, psychological treatment preferred. SSRIs first line if drug treatment needed. SSRIs continue to be first line medication for the treatment of depression. Escitalopram (now generic) offers the best balance of acceptability and risk. Mirtazapine is non-ssri alternative. Switching within or between class is a reasonable option if a patient with depression is insufficiently helped by an initial SSRI Augmentation with low dose atypical antipsychotic drugs is probably effective but the adverse effect burden is troublesome. Utility vs lithium needs exploring Ketamine might provide symptomatic relief for patients who have persistent depressive symptoms despite multiple trials of psychological and pharmacological treatment
Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationRecent Advances in the Treatment of Major Depression
Recent Advances in the Treatment of Major Depression Antidepressant Drugs: Unmet Needs in 2015 Limited efficacy (~ 10-20% advantage vs PBO in RCTs) Intolerable side effects for some Inconsistent effects
More informationPharmacological treatment of anxiety disorders where is
Pharmacological treatment of anxiety disorders where is the room for improvement? David S Baldwin, Professor of Psychiatry BAP Masterclass, 15 th April 2011 dsb1@soton.ac.uk Declaration of interests (last
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationPharmacotherapy of depression
Pharmacotherapy of depression Stuff you already know Stuff you probably know Stuff you possibly don t know Stuff you thought you knew but are mistaken about How long does it take for antidepressants
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationTreatment strategies in major depression What to use when?
Treatment strategies in major depression What to use when? Michael Bauer, MD, PhD Professor and Chair of Psychiatry University Hospital Carl Gustav Carus Technische Universität Dresden Germany First-line
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationforeword general general Six Persimmons 六柿圖 other modalities of treatments by evidence or impression? anxiety disorders drugs benzodiazepines
Clinical Updates Management of Anxiety Disorders John So - Psychiatrist foreword Six Persimmons 六柿圖 MuqiFachang 牧谿法常 after Zen meditation mindfulness other trends of psychotherapy other modalities of treatments
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationGuidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014)
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014) Date of Preparation: September 2014 Date for next full
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationMajor Depression and Anxiety in Adolescents and Adults
Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize
More informationSetting ambitious goals for patients with depression with a focus on functional recovery
Setting ambitious goals for patients with depression with a focus on functional recovery The role of the overlooked cognitive symptoms in the treatment of depression Dr Andreas Papadopoulos Locum Consultant
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationPharmacotherapy of Depression: State of the Art and Future Directions Michael E. Thase, MD
Pharmacotherapy of Depression: State of the Art and Future Directions Michael E. Thase, MD University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh
More informationTreatment of Anxiety (without benzos)
Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationDIAGNOSTIC CRITERIA (ICD 10)
DEPRESSION Depression is a major public health problem around the world Affects 1:5 older people living in the community Affects 2:5 older people living in care homes Various treatment options available,
More informationOptimal Treatment of Anxiety Disorders
Optimal Treatment of Anxiety Disorders Franklin R. Schneier, MD Co-Director, Anxiety Disorders Clinic Research Psychiatrist New York State Psychiatric Institute Special Lecturer in Psychiatry Columbia
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Step 3: GAD with marked functional impairment or that has not improved after step 2 interventionsentions bring together everything NICE says on a topic in an interactive flowchart. are interactive and
More informationGuidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.1 December 2018) Date of Preparation: January 2018 (with addition of
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationMental illness A Broad Overview. Dr H Pathmanandam March 2017
Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationThe pharmacological management of anxiety disorders
Stephen Bleakley MRPharmS, MCMHP Review in association with The pharmacological management of anxiety disorders Progress in Neurology and Psychiatry is running a series of articles on the major psychiatric
More information3. Depressione unipolare
3. Depressione unipolare Depressione unipolare con mancata risposta al trattamento con SSRI Question: Should switching from SSRIs to another antidepressant class vs switching within class (SSRIs) be used
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationPSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust
PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions
More informationANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN
UW PACC Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationAnxiolytics. What s new? Lindsey Sinclair
Anxiolytics Lindsey Sinclair David Nutt What s new? pregabalin has gained a licence for the treatment of generalized anxiety disorder new data support the use of escitalopram in several anxiety disorders
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationClinical Update on Management of Depression and Anxiety in the Primary Care Setting. Objectives: Why Is This Important?
Clinical Update on Management of Depression and Anxiety in the Primary Care Setting Kirstyn Kameg, DNP, PMHNP, BC University Professor PMHNP Program Coordinator Robert Morris University November 4, 2017
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationAugmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression
CNS Drugs (2013) 27 (Suppl 1):S11 S19 DOI 10.1007/s40263-012-0029-7 REVIEW ARTICLE Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression Masaki
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationRecommendation 1: Diagnosis of Generalized Anxiety Disorder (IΙΙ-2)
Final GAD RECOMMENDATIONS & EVIDENCE Recommendation 1: Diagnosis of Generalized Anxiety Disorder (IΙΙ-2) It is recommended for general practitioners and other Primary Health Care doctors to consider the
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services ANXIETY DISORDERS This guideline covers a range of anxiety disorders, including generalised anxiety disorder, social
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationDepression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
More informationPharmacological Treatment of Anxiety & Depressive Disorders
Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
More informationDEPRESSION Depression is a major public health problem around the world Affects 1:5 older people living in the community Affects 2:5 older people living in care homes Various treatment options available,
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationPresenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy
Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Robert L Page II, Pharm.D., MSPH, FHFSA, FCCP, FAHA Professor of Clinical Pharmacy Clinical Specialist, Division of Cardiology University of Colorado
More informationFor: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013
For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please
More informationTreatment Management and the
Evidence-based Sequenced Treatment Management and the 2010 APA Practice Guideline George I. Papakostas, MD Director, Treatment-Resistant Depression Studies Department of Psychiatry Massachusetts General
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationAnxiety Disorders- OCD. Peter Giacobbe MD FRCPC L. Ravindran MD FRCPC
Anxiety Disorders- OCD Peter Giacobbe MD FRCPC L. Ravindran MD FRCPC Anxiety Disorders - Epidemiology Anxiety disorders are the most common class of mental disorders Estimated lifetime prevalence rates
More informationPsychiatric Consultant Role in Collaborative Care Sept 12, 2013
New York State Collaborative Care Initiative Psychiatric Consultant Role in Collaborative Care Sept 12, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update 1 Guideline title Anxiety: management of generalised anxiety disorder in adults in primary, secondary and community care (update)
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationSome newer, investigational approaches to treating refractory major depression are being used.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Depression and Anxiety Disorders Mood and anxiety disorders are common, and the mortality risk is due primarily to suicide, cardiovascular
More informationAdverse events of common psychiatric medications: an umbrella review
Adverse events of common psychiatric medications: an umbrella review Katrina Bartellas, 1 Thomas Bajorek 1 Sarah Stockton, 1 Stefan Leucht, 2 Andrea Cipriani, 1 Seena Fazel 1 1 Department of Psychiatry,
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationManagement of. Depression: Some observations
Management of Psychobiology Research Group Depression: Some observations Hamish McAllister-Williams Reader in Clinical Psychopharmacology, Newcastle University Hon. Consultant Psychiatrist, Regional Affective
More informationFROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY
13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD
More informationDisclosures. Overview of Workshop. Objectives. Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression
Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression Disclosures The speakers have no disclosures. Lisa Ochoa-Frongia, MD Christina Mangurian, MD, MAS L. Elizabeth
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationESCITALOPRAM. THERAPEUTICS Brands Lexapro see index for additional brand names. Generic? Yes
ESCITALOPRAM THERAPEUTICS Brands Lexapro see index for additional brand names Generic? Yes Class SSRI (selective serotonin reuptake inhibitor); often classified as an antidepressant, but it is not just
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationDisclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017
Psychopharmacology of Pediatric Anxiety and Depression Susan Sharp, DO Clinical Assistant Professor of Child and Adolescent Psychiatry Kansas University Medical Center The Children's Mercy Hospital, 2017
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 12 June 2013 SEROPLEX 5 mg, film-coated tablet B/14 (CIP: 3400936428973) B/28 (CIP: 3400935993519) SEROPLEX 10 mg,
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationA Review of the Role of Antipsychotics as an Augmentation Agent or Treatment Option for Patients with Treatment Resistant Unipolar Depression
International Journal of Emergency Mental Health and Human Resilience, Vol. 17, No.2, pp. 476-480, ISSN 1522-4821 A Review of the Role of Antipsychotics as an Augmentation Agent or Treatment Option for
More information